Business Wire

BARTEK-INGREDIENTS

25.1.2023 21:05:42 CET | Business Wire | Press release

Share
Bartek Hosts Canadian Government Dignitaries at Facility Groundbreaking

Bartek Ingredients advances its plans to strengthen its position as the world’s largest producer of malic and food-grade fumaric acid with the groundbreaking of its state-of-the-art, $175 million malic and fumaric acid production facility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005653/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Left to right: Tim Larson (Bartek), Minister Neil Lumsden, MP Chad Collins, Minister Lisa Thompson, Hamid Goli (Bartek), Jose Kafie (Bartek), John Burrows (Bartek), Jim Vincent (Bartek), Steven Chambers (Bartek), Minister Vic Fedeli. (Photo: Business Wire)

The company held a groundbreaking ceremony on Jan. 12 with Canadian government officials and local community leaders to celebrate the official commencement of the construction project.

“We are thrilled to be breaking ground on our new facility which will set a new global benchmark for safety, efficiency, and environmental performance,” Bartek President and CEO John Burrows said. “We are pleased to be investing in the community of Stoney Creek and proud to play an integral part in supporting local industries and the local economy. We are thankful for our partnerships with the provincial and federal government and Environment Hamilton and their support and guidance throughout the process.”

Among those in attendance at the groundbreaking were Neil Lumsden, Minister of Tourism, Culture and Sport and Member of Provincial Parliament for Hamilton East, Victor Fedeli, Minister of Economic Development and Trade, Lisa Thompson, Minister of Agriculture, Food and Rural Affairs, and Chad Collins, Member of Federal Parliament for Hamilton East-Stoney Creek.

“Congratulations to everyone at Bartek Ingredients on this exciting milestone,” Minister Fedeli said. “Bartek’s $175 million investment will ensure that the company can continue to expand and create more good-paying jobs in Hamilton and the surrounding region. Together, we’re building a stronger Ontario with opportunities for all people.”

The facility will double Bartek’s production capacity and propel new product development and other innovation efforts. It is also being built with sustainability in mind and is expected to be the most environmentally sustainable facility in the industry – projected to reduce per unit greenhouse gas emissions by more than 80 percent.

“Ontario has a clean energy advantage and is a sustainable and predictable place to do business,” Minister Piccini said. “As a result, we’re attracting the jobs of tomorrow. My Ministry was proud to work closely with Bartek through the permitting and approvals process to help secure this significant investment to Ontario.”

Minister Thompson added: “Bartek’s new state-of-the-art facility will be a shining example of Ontario’s robust agri-food manufacturing and processing sector. This major investment will create good-paying jobs in the local community and further strengthen Ontario’s value-added food supply chain.”

Through this project, Bartek will inject $100 million into the local Stoney Creek economy. The facility is expected to be fully operational at the beginning of 2024.

“Hamilton’s Bartek facility will soon become one of the world’s largest malic and food-grade acid production plants,” Minister Lumsden said. “Our government is excited to see local manufacturers, such as Bartek, invest in Ontario to grow and create more good-paying jobs right here in Hamilton!”

For more information, please visit bartek.ca or contact Bartek at info@bartek.ca.

About Bartek Ingredients

For over 50 years, Bartek Ingredients Inc. has been a leading global manufacturer of malic acid, fumaric acid, and maleic anhydride. Headquartered in Stoney Creek, Ontario, Canada, Bartek employs 120 people across its two production facilities in Southern Ontario. Bartek’s facilities are registered to the ISO 9001:2015 Standard. Bartek also holds the BRC Global Standard for Food Safety certification, and it distributes to more than 40 countries around the world. With new ownership in 2019 and significant investments, Bartek’s presence in the food and beverage space continues to be bolstered by highly innovative products and services that utilize deep product expertise and application knowledge to offer solutions to industry needs. For more information about Bartek, visit bartek.ca/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005653/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye